Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

355 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Androgen receptor inhibitor-induced "BRCAness" and PARP inhibition are synthetically lethal for castration-resistant prostate cancer.
Li L, Karanika S, Yang G, Wang J, Park S, Broom BM, Manyam GC, Wu W, Luo Y, Basourakos S, Song JH, Gallick GE, Karantanos T, Korentzelos D, Azad AK, Kim J, Corn PG, Aparicio AM, Logothetis CJ, Troncoso P, Heffernan T, Toniatti C, Lee HS, Lee JS, Zuo X, Chang W, Yin J, Thompson TC. Li L, et al. Among authors: azad ak. Sci Signal. 2017 May 23;10(480):eaam7479. doi: 10.1126/scisignal.aam7479. Sci Signal. 2017. PMID: 28536297 Free PMC article.
Targeting the MYCN-PARP-DNA Damage Response Pathway in Neuroendocrine Prostate Cancer.
Zhang W, Liu B, Wu W, Li L, Broom BM, Basourakos SP, Korentzelos D, Luan Y, Wang J, Yang G, Park S, Azad AK, Cao X, Kim J, Corn PG, Logothetis CJ, Aparicio AM, Chinnaiyan AM, Navone N, Troncoso P, Thompson TC. Zhang W, et al. Among authors: azad ak. Clin Cancer Res. 2018 Feb 1;24(3):696-707. doi: 10.1158/1078-0432.CCR-17-1872. Epub 2017 Nov 14. Clin Cancer Res. 2018. PMID: 29138344 Free PMC article.
Enzalutamide and CXCR7 inhibitor combination treatment suppresses cell growth and angiogenic signaling in castration-resistant prostate cancer models.
Luo Y, Azad AK, Karanika S, Basourakos SP, Zuo X, Wang J, Yang L, Yang G, Korentzelos D, Yin J, Park S, Zhang P, Campbell JJ, Schall TJ, Cao G, Li L, Thompson TC. Luo Y, et al. Among authors: azad ak. Int J Cancer. 2018 May 15;142(10):2163-2174. doi: 10.1002/ijc.31237. Epub 2018 Jan 30. Int J Cancer. 2018. PMID: 29277895 Free PMC article.
BRM Promoter Polymorphisms and Survival of Advanced Non-Small Cell Lung Cancer Patients in the Princess Margaret Cohort and CCTG BR.24 Trial.
Liu G, Cuffe S, Liang S, Azad AK, Cheng L, Brhane Y, Qiu X, Cescon DW, Bruce J, Chen Z, Cheng D, Patel D, Tse BC, Laurie SA, Goss G, Leighl NB, Hung R, Bradbury PA, Seymour L, Shepherd FA, Tsao MS, Chen BE, Xu W, Reisman DN. Liu G, et al. Among authors: azad ak. Clin Cancer Res. 2017 May 15;23(10):2460-2470. doi: 10.1158/1078-0432.CCR-16-1640. Epub 2016 Nov 8. Clin Cancer Res. 2017. PMID: 27827316 Free PMC article. Clinical Trial.
Validation of microRNA pathway polymorphisms in esophageal adenocarcinoma survival.
Faluyi OO, Eng L, Qiu X, Che J, Zhang Q, Cheng D, Ying N, Tse A, Kuang Q, Dodbiba L, Renouf DJ, Marsh S, Savas S, Mackay HJ, Knox JJ, Darling GE, Wong RK, Xu W, Azad AK, Liu G. Faluyi OO, et al. Among authors: azad ak. Cancer Med. 2017 Feb;6(2):361-373. doi: 10.1002/cam4.989. Epub 2017 Jan 11. Cancer Med. 2017. PMID: 28074552 Free PMC article.
355 results